Today: 19 April 2026
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears
8 April 2026
2 mins read

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

UPDATE: New York, April 8, 2026, 11:24 (EDT)

IREN last changed hands at $36.62, gaining roughly 2.5% over the previous close. The stock whipped around, printing anywhere from $36.08 to $39.50, with volume topping 16.1 million shares. Volatility is sticking, as investors keep balancing the company’s AI expansion story against the threat of dilution.

IREN’s February report showed roughly $2.8 billion in cash as of January 31. The company has locked in over $9.2 billion in funding so far this year, coming from customer prepayments, convertible notes, GPU leasing, and GPU financing.

The update also noted IREN’s grid-connected power now tops 4.5 gigawatts—this figure includes the newly added 1.6GW campus in Oklahoma. At Prince George, roughly $0.4 billion in AI-cloud ARR has been locked in through existing contracts, and talks to secure more than $0.5 billion in additional ARR are ongoing.

NEW YORK, April 8, 2026, 09:17 EDT

Shares of IREN climbed Wednesday, last quoted at $35.74 for a 1.8% gain from the previous close. Investors are weighing optimism around the company’s AI infrastructure push against the price tag of those projects. Still, the stock sits more than 50% below its high, according to a note late Tuesday.

IREN’s pivot away from bitcoin mining—aiming for AI cloud services instead—has suddenly shot into focus. Investors are being asked to fund the move well ahead of any substantial new revenue. Fresh commentary split quickly: some voices calling for a buy-the-dip approach, others flagging that the $6 billion at-the-market share program could keep the threat of dilution hanging over current shareholders.

On March 4, the company said it struck a deal to buy upwards of 50,000 Nvidia B300 GPUs—the same chips at the heart of AI training and inference systems. The new order brings its target to 150,000 GPUs total. IREN figures that kind of hardware could support more than $3.7 billion in annualized AI cloud run-rate revenue by the end of 2026, though those figures come from its own models and aren’t guaranteed.

Snagging hardware ahead of the crowd slashes “time-to-compute” and boosts “execution certainty,” according to Daniel Roberts, IREN co-founder and now co-CEO. Back in February, Roberts described IREN’s demand backdrop as the “strongest” the company has seen so far. IREN has tallied its GPU financing at $3.6 billion, and says Microsoft’s $1.9 billion prepayment covers 95% of the GPU-linked capital requirements. IREN

Microsoft sits at the center of this story. In November, IREN rolled out a five-year AI cloud agreement with the tech giant, worth $9.7 billion—deployments staggered through 2026, with goals circling $1.9 billion in annualized revenue. Reuters pointed out then that the deal was meant to tackle the AI computing crunch.

The numbers don’t paint a pretty picture for investors. IREN’s Feb. 5 results put revenue at $184.7 million—a sizable drop from $240.3 million in the previous quarter. The company ended up with a net loss of $155.4 million. Still, management emphasized that it’s making progress shifting capacity from bitcoin mining over to AI-centric workloads.

IREN isn’t alone in making an AI pivot. In December, Hut 8 signed a $7 billion AI data center lease, and Applied Digital credited surging AI demand in January for its strong quarterly results. It’s a pattern: former crypto-focused operators now scrambling for scarce power and compute capacity.

But there’s no clear takeaway from the latest options flow. According to TheFly, about 103,000 contracts changed hands on Tuesday, with calls leading the way and driving the put/call ratio down to 0.29. That low reading usually points to a bullish bias, though the sentiment tag still came in as mixed. Implied volatility sat near 100.55, pricing in daily moves of roughly $2.21.

Worries about dilution are easier to track now. On March 4, IREN scrapped its old $1 billion share-sale authorization and rolled out a new at-the-market program, or ATM, this time boosting the ceiling to $6 billion. The company had already sold 66.7 million shares under the previous plan, raising $1 billion. In an ATM setup, IREN sells shares in chunks rather than flooding the market all at once.

No illusions about the risk: IREN’s $3.7 billion revenue target depends on chips arriving, construction sticking to schedule, asset utilization, price holds, and landing more contracts. The company cautions that reported revenue could diverge sharply. Right now, shares sit in limbo—AI potential on paper, numbers unfinished.

Stock Market Today

  • Strategist Predicts Stock Rally from Iran Ceasefire and Q1 Earnings
    April 19, 2026, 5:42 AM EDT. A market strategist forecasts a significant stock rally driven by a ceasefire in the Iran conflict and stronger first-quarter corporate earnings. The strategist highlights how easing geopolitical tensions, particularly the Iran war ceasefire, can reduce market uncertainty, boosting investor confidence. Additionally, upcoming Q1 earnings reports are expected to showcase robust corporate performance, further propelling stock prices higher. Analysts suggest that these factors combined could create a favorable environment for equities, signaling potential gains in the near term. Investors are advised to monitor both geopolitical developments and earnings season closely as catalysts for market movements.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 19.04.2026

19 April 2026
LIVEMarkets rolling coverageStarted: April 19, 2026, 12:00 AM EDTUpdated: April 19, 2026, 5:44 AM EDT Humana (HUM) Valuation Highlights Volatility and Future Growth Potential April 19, 2026, 5:44 AM EDT. Humana (ticker: HUM) has seen volatile share price movements recently, with a 21% gain over one month contrasting a 25% decline over three months. The stock trades at $205.14, slightly below its narrative fair value of $212.87, suggesting it may be undervalued. Analysts highlight Medicare Advantage expansion as a key growth driver, emphasizing that robust compliance and data-driven operations will be critical for sustained profitability. Total shareholder returns over one
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet
Previous Story

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

US Stock Market Today: Live Updates 09.04.2026

Go toTop